Engineering bacteria for enhanced tumor therapy: from surface modification to synthetic genetic circuits

Area of Science:

• Oncology
• Immunotherapy
• Synthetic Biology

Background:

• Bacterial therapy offers a promising approach for cancer treatment, leveraging bacteria-mediated immunotherapy for tumor regression.
• Naturally occurring bacteria, like facultative anaerobes, exhibit advantages such as biocompatibility and self-propulsion, enhancing tumor accumulation via the enhanced permeability and retention (EPR) effect.

Purpose of the Study:

• To review advancements in bacteria-mediated cancer immunotherapy, focusing on administration routes, surface engineering, and synthetic gene circuit design.
• To summarize historical progress, advantages, and challenges of bacterial therapy for cancer treatment.
• To highlight clinical translation prospects and necessary safety measures for large-scale applications.

Main Methods:

• Discussion of bacterial administration routes and surface modification strategies (ionic interactions, covalent bonding, nanomaterial coating).
• Exploration of gene editing and synthetic genetic circuit design for enhanced bacterial functions.
• Comprehensive review of existing literature on bacterial therapy in cancer immunotherapy.

Main Results:

• Surface modifications and genetic engineering can mitigate native bacterial toxicity and improve tumor targeting and colonization.
• Synthetic gene circuits offer precise control over bacterial behavior, enhancing anticancer functions and biosafety.
• Bacterial therapy demonstrates potential for disrupting tumor metabolism, inducing apoptosis, and stimulating anticancer immune responses.

Conclusions:

• Bacterial therapy, particularly with engineered bacteria, holds significant potential for cancer treatment by enhancing immunotherapy and drug delivery.
• Further research into synthetic gene circuit design and rigorous safety assessments are crucial for successful clinical translation.
• Addressing challenges in biosafety and unintended immune responses is essential for the widespread clinical application of bacteria-mediated tumor therapy.